Peptide record

TPDB91317

Crabrolin Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity modified_plain modified
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91317
Crabrolin
Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 iACP-DRLF Antifungipept APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
modified_plain
Yes
A 13-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FLPLILRKIVTAL-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
13 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
European hornet (Vespa crabro) Activity
Evidence Records 5 records
Evidence 1 Activity

Activity

IC50
IC50 = 27.71 µM
Anticancer
27.71 µM

Target

Lung Cancer
H-838
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 32.13 µM
Anticancer
32.13 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 3 Activity

Activity

IC50
IC50 = 20.13 µM
Anticancer
20.13 µM

Target

Brain Tumor
U-251-MG
Brain

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 4 Activity

Activity

IC50
IC50 = 8.539 µM
Anticancer
8.539 µM

Target

Colon Cancer
HCT-116
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 5 Activity

Activity

IC50
IC50 = 26.49 µM
Anticancer
26.49 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023